Skip to main content

In Vitro Long-Term Proliferation Assays to Study Antiproliferative Effects of PARP Inhibitors on Cancer Cells

  • Protocol
  • First Online:
Poly(ADP-Ribose) Polymerase

Part of the book series: Methods in Molecular Biology ((MIMB,volume 1608))

Abstract

Cell proliferation assays are an important component of small molecule inhibitor screens for cancer therapies. An important but often overlooked variable involves the timing and timeframe of inhibitor treatment. Whereas many traditional chemotherapeutics kill or inhibit proliferation on the timeframe of hours or in a few days of treatment, more targeted therapies that affect other cancer-relevant pathways, including differentiation or cell stress responses, can take longer, often several days to weeks to impact cellular growth and survival. Many poly(ADP-ribose) polymerases (PARPs) are involved in cellular stress pathways; therefore, phenotypic effects of PARP inhibition are often only observed with long-term inhibitor treatment. Here we summarize several assays for analyzing long-term proliferation of both adherent and suspension cells, relying either on growth in two-dimensional tissue culture or on systems than enable growth in 3D.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.00
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Kraus WL (2015) PARPs and ADP-ribosylation: 50 years … and counting. Mol Cell 58:902–910. doi:10.1016/j.molcel.2015.06.006

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Jones P, Wilcoxen K, Rowley M, Toniatti C (2015) Niraparib: a poly(ADP-ribose) polymerase (PARP) inhibitor for the treatment of tumors with defective homologous recombination. J Med Chem 58:3302–3314. doi:10.1021/jm5018237

    Article  CAS  PubMed  Google Scholar 

  3. Bryant HE, Schultz N, Thomas HD et al (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434:913–917. doi:10.1038/nature03443

    Article  CAS  PubMed  Google Scholar 

  4. Farmer H, McCabe N, Lord CJ et al (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434:917–921. doi:10.1038/nature03445

    Article  CAS  PubMed  Google Scholar 

  5. Jones P, Altamura S, Boueres J et al (2009) Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors. J Med Chem 52:7170–7185. doi:10.1021/jm901188v

    Article  CAS  PubMed  Google Scholar 

  6. Gaymes TJ, Shall S, MacPherson LJ et al (2009) Inhibitors of poly ADP-ribose polymerase (PARP) induce apoptosis of myeloid leukemic cells: potential for therapy of myeloid leukemia and myelodysplastic syndromes. Haematologica 94:638–646. doi:10.3324/haematol.2008.001933

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Mukhopadhyay A, Elattar A, Cerbinskaite A et al (2010) Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors. Clin Cancer Res 16:2344–2351. doi:10.1158/1078-0432.CCR-09-2758

    Article  CAS  PubMed  Google Scholar 

  8. Lau T, Chan E, Callow M et al (2013) A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth. Cancer Res 73:3132–3144. doi:10.1158/0008-5472.CAN-12-4562

    Article  CAS  PubMed  Google Scholar 

  9. Daigle SR, Olhava EJ, Therkelsen CA et al (2011) Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 20:53–65. doi:10.1016/j.ccr.2011.06.009

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Knutson SK, Wigle TJ, Warholic NM et al (2012) A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat Chem Biol 8:890–896. doi:10.1038/nchembio.1084

    CAS  PubMed  Google Scholar 

  11. Franken NAP, Rodermond HM, Stap J et al (2007) Clonogenic assay of cells in vitro. Nat Protoc 1:2315–2319. doi:10.1038/nprot.2006.339

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Heike Keilhack .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer Science+Business Media LLC

About this protocol

Cite this protocol

Keilhack, H., Chang, P. (2017). In Vitro Long-Term Proliferation Assays to Study Antiproliferative Effects of PARP Inhibitors on Cancer Cells. In: Tulin, A. (eds) Poly(ADP-Ribose) Polymerase. Methods in Molecular Biology, vol 1608. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-6993-7_21

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-6993-7_21

  • Published:

  • Publisher Name: Humana Press, New York, NY

  • Print ISBN: 978-1-4939-6992-0

  • Online ISBN: 978-1-4939-6993-7

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics